Abstract:Rationale: Neuroblastoma is a common abdominal malignancy in children. The chemoresistant and relapsed cases have poor prognosis. The genetic background and the mechanism of resistance remain unelucidated. Next-generation sequence (NGS) is becoming a popular tool to unravel the genetic background and to guide precision medicine in oncology studies as well as in clinical practice. Patient concerns: Here we report a neuroblastoma case of a boy aged 2 years and 8 months when first diagnosed, with multiple metastatic sites found in both lungs. The metastatic tumors were resistant to chemotherapy and the patient suffered from severe bone marrow suppression. NGS of the whole exon revealed somatic mutations including 9666 single-nucleotide variants (SNVs) from 5148 genes, 55 copy number variations (CNVs), and 140 insertion-deletion variations. The high frequency of SNVs makes it distinguished case. However, no mutation of key tumor driver genes with functional significance was identified. No abnormality was found in nucleic acid synthesis enzymes. No amplification of c-Myc and n-Myc was found by fluorescence in situ hybridization (FISH). Both NGS and immunohistochemistry (IHC) analysis indicated that DNA mismatch repair (MMR) system was intact. Interventions: After initial diagnosis, the patient received combinational chemotherapy, which includes vindesine, an analogue of adriamycin suggested by NGS data, for 4 months. Radical section of the tumor together with the left kidney and the left adrenal gland was performed 5 months after diagnosis. Postsurgical chemotherapy protocols was similar with the previous. Outcomes: The patient died 2 years after initial diagnosis after 8 relapses following combinational chemotherapy. Lessons: This case of neuroblastoma is with pronounced somatic mutations but unidentified driver gene and therapeutic target. AlthoughNGSis a potentially powerful tool to guideprecision medicine, at current stage, its application in the clinic certainly has its limits. The underlying mechanism of the substantially increased SNV number, as well as the malignant behaviors of the tumor, is yet to be revealed.

Lack of classical astroblastoma features in pediatric MN1::BEND2-fused brain tumors

Spinal astroblastoma, MN1 altered in 3‐year‐old child: An uncommon tumor at an unusual site

Astroblastoma With a Novel YAP1::BEND2 Fusion: A Case Report

A primary intracranial neuroepithelial neoplasm with novel TCF3::BEND2 fusion: a case report

P20.21.A SPINAL CORD ASTROBLASTOMA WITH EWSR1-BEND2 FUSION IN FEMALE PATIENTS: A REPORT OF FOUR CASES FROM CHINA AND A COMPREHENSIVE LITERATURE REVIEW

Aggressive Pediatric Primitive Round Cell Tumors with MN1::ZNF341 Fusion: A Mimic of Neuroblastoma

Pediatric Mesenchymal Tumor With MN1::TAF3 Fusion

Spinal Cord Astroblastoma With EWSR1-BEND2 Fusion in Female Patients : A Report of Four Cases From China and a Comprehensive Literature Review

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

The spectrum of morphological findings in pediatric central nervous system MN1-fusion-positive neuroepithelial tumors

Clinical and Biological Features of Neuroblastic Tumors: A Comparison of Neuroblastoma and Ganglioneuroblastoma.

Spindle Cell Neoplasm With a Novel MN1::TAF3 Fusion: A Rare Case in a Toddler

Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas

NFB-06. TREATMENT CHALLENGES IN PEDIATRIC GLIOBLASTOMA MULTIFORME WITH CONCURRENT SOMATIC AND GERMLINE NF1 MUTATIONS WITH GERMLINE MISMATCH REPAIR MUTATIONS: TWO UNIQUE CASES

Rare Oncogenic Fusions in Pediatric Central Nervous System Tumors: A Case Series and Literature Review

Exome sequencing identifies predisposing and fusion gene in ganglioneuroma, ganglioneuroblastoma and neuroblastoma.

PDCT-02. UNIQUE CONCURRENT ASSOCIATION OF SOMATIC AND GERMLINE NF1 MUTATIONS WITH GERMLINE MISMATCH REPAIR MUTATIONS IN PEDIATRIC GLIOBLASTOMA MULTIFORME

Poor outcome in congenital mesoblastic nephroma with TPM3::NTRK1 fusion: a case report from multi-disciplinary treatment to molecular tumor board

Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment

Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549–BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification

Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes